Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Lab-on-a-Chip Approach Advances Immune–Cancer Cell Interaction Analysis

By LabMedica International staff writers
Posted on 19 Jun 2026

Conventional cytotoxicity assays often average responses across thousands of cells, obscuring how individual immune cells engage and kill tumor cells. More...

For immunotherapy evaluation, the precise sequence of cell contact, activation, and later tumor-cell death can be decisive, but is rarely captured in standard workflows. Single-cell, time-based readouts remain challenging in many laboratories. Researchers now present an instrument-free lab-on-a-chip approach that visualizes immune–cancer cell interactions over time in high detail.

At the Technical University of Munich (TUM), investigators developed CellTrap, a microfluidic lab-on-a-chip platform designed to study discrete cell-to-cell contacts. The device features a large main channel that branches into 1,024 trapping chambers, where individual immune cells and cancer cells can be co-localized and immobilized. These interactions are then tracked by time-lapse microscopy for up to 14 hours, enabling continuous observation of contact formation, immune activation, and target-cell killing. The platform supports diverse experimental contexts, including cancer cells alone, immune cells alone, and varied immune-to-cancer cell ratios, while operating on a standard fluorescence microscope without specialized equipment.

Initial experiments using a glioblastoma cell line showed that tumor cells were attacked more frequently and intensely when several immune cells encountered a single target. The observations also indicated that early activation signals in immune cells often foreshadowed later cell-damaging effects, linking initiation events to outcomes within the same interaction. Beyond glioblastoma, CellTrap was tested with two additional cancer cell lines, chronic myeloid leukemia and adenocarcinoma, demonstrating applicability across different tumor contexts.

Details of the work are published in RSC Advances on April 10, 2026, under the title “CellTrap: an instrument-free microfluidic platform for cell–cell interactions at stochastically generated effector-to-target ratios.” The authors highlight that the approach enables direct visualization of how early cellular responses relate to later consequences in individual pairings, information that is typically inaccessible in bulk assays. The platform’s design emphasizes simplicity and affordability by leveraging existing fluorescence microscopy infrastructure commonly available in research labs.

“With CellTrap, we can not only measure whether immune cells kill cancer cells, but also track when and under what conditions this occurs. This matters, because immune responses can vary so much from one cell to the next. And we deliberately kept the platform simple and affordable: it runs on a standard fluorescence microscope of the kind most labs already have, with no specialised equipment,” said Ghulam Destgeer, Professor of Control and Manipulation of Microscale Living Objects at the TUM School of Computation, Information and Technology.

“The more we learn about what actually happens between individual cells, the better we can compare treatment strategies and develop new ones. And although we focused on immune and cancer cells, the platform isn’t limited to them — almost any combination of cells can be loaded and observed in the chip,” said Destgeer.

Related Links
TUM


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Blood proteins measured years before diagnosis may signal future prostate cancer risk, including aggressive disease.(Image Credit: iStock)

Blood Proteins Reveal Signals Linked to Prostate Cancer Risk Years Before Diagnosis

Prostate cancer is the most commonly diagnosed cancer in men worldwide. While many tumors grow slowly, aggressive forms can be life-threatening, underscoring the need for earlier risk identification.... Read more

Pathology

view channel
Image Credit: iStock

AI Tissue Analysis May Help Identify Missed Precancerous Colon Polyps

Colorectal cancer is diagnosed in an estimated 1.9 million people worldwide each year, often without symptoms in its early stages. Timely detection of precancerous lesions is therefore important, yet some... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: Beginning in 2027, Quest will provide access to the Onclarity Self-Collection Kit through clinician, health plan, and consumer-initiated testing channels, along with its patient service center network.

Collaboration to Expand Cervical Cancer Screening Access With At-Home HPV Collection

Cervical cancer is largely preventable with regular screening and early detection of human papillomavirus (HPV), the leading cause of the disease. Screening gaps persist, in part because traditional sample... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.